Lycia Therapeutics (LYTH) Registration filing summary

Company overview and business model

• Clinical-stage biotech developing LYTAC degraders to eliminate disease-causing extracellular proteins, initially for autoimmune, inflammatory and allergic diseases.

• LYTACs shuttle extracellular targets to lysosomes for degradation; cataLYTACs recycle to degrade multiple target molecules, while classic LYTACs degrade with the target.

• Clinical pipeline: LCA-0061 and LCA-0062 target IgE in food allergy and other allergic diseases; LCA-0321 targets Graves’ disease autoantibodies.

• Strategy prioritizes early Phase 1 pharmacodynamic and biomarker proof of concept, expansion into additional IgE indications, new targets, platform development and selective collaborations.

Financial performance and metrics

• Collaboration revenue was $14.9M in FY2024 and $6.7M in FY2025; revenue fell as the Lilly collaboration wound down and ended in February 2026.

• Net loss was $26.5M in FY2024 and $36.5M in FY2025; R&D expense was $41.1M and $40.5M, respectively.

• H1 2026 net loss was $19.2M vs. $25.6M H1 2025; R&D was $17.3M vs. $25.8M, and operating cash use was $18.1M vs. $35.7M.

• Cash, cash equivalents and marketable securities totaled $148.1M at June 30, 2026; accumulated deficit was $136.8M.

• No product-sale revenue; substantial losses are expected to continue, and additional capital will be needed beyond the offering and existing resources.

Use of proceeds and capital allocation

• Net proceeds and existing liquidity are intended to fund clinical development of LCA-0061, LCA-0062 and LCA-0321, other R&D, working capital and general corporate purposes.

• Proceeds may also support in-licensing, acquisitions or investments in complementary products or technologies; no such transaction was committed or under negotiation.

• Management retains broad discretion over proceeds; anticipated proceeds and existing cash will not fund candidates through regulatory approval and commercialization.